Synthesis and biological activity of some derivatives of rifamycin P - PubMed (original) (raw)
Comparative Study
doi: 10.1021/jm00167a029.
Affiliations
- PMID: 2329569
- DOI: 10.1021/jm00167a029
Comparative Study
Synthesis and biological activity of some derivatives of rifamycin P
B Cavalleri et al. J Med Chem. 1990 May.
Abstract
A series of derivatives of rifamycin P, an antibiotic produced by fermentation of a mutant strain of Nocardia mediterranea or by chemical modification of rifamycin S, have been prepared. The structures of these compounds were determined by 1H NMR, IR, UV, and LC/MS. Their in vitro and in vivo antibacterial activities in comparison with rifampicin and two other rifamycins under investigation were evaluated. The derivatives were more active than rifamycin P against Mycobacterium avium complex and other slowly and rapidly growing nontuberculous mycobacteria which frequently cause systemic infection in patients with AIDS. 2'-(Diethylamino)rifamycin P (P/DEA) appears suitable for further investigation.
Similar articles
- Novel rifamycins. I-Synthesis and antibacterial activity of 3-hydrazinorifamycin derivatives.
Marsili L, Franceschi G, Gioia B, Oronzo G, Schioppacassi G, Vigevani A. Marsili L, et al. Farmaco Sci. 1982 Oct;37(10):641-50. Farmaco Sci. 1982. PMID: 6814953 - Rifamycin derivatives active against pathogenic rapidly-growing mycobacteria.
Combrink KD, Ramos AR, Spring S, Schmidl S, Elizondo K, Morin P, De Jesus B, Maurer FP. Combrink KD, et al. Bioorg Med Chem Lett. 2019 Aug 15;29(16):2112-2115. doi: 10.1016/j.bmcl.2019.07.001. Epub 2019 Jul 2. Bioorg Med Chem Lett. 2019. PMID: 31281018 - New rifamycins modified at positions 3 and 4. Synthesis, structure and biological evaluation.
Marsili L, Pasqualucci CR, Vigevani A, Gioia B, Schioppacassi G, Oronzo G. Marsili L, et al. J Antibiot (Tokyo). 1981 Aug;34(8):1033-8. doi: 10.7164/antibiotics.34.1033. J Antibiot (Tokyo). 1981. PMID: 7319919 - Recent trends in rifamycin research.
Lal R, Lal S. Lal R, et al. Bioessays. 1994 Mar;16(3):211-6. doi: 10.1002/bies.950160313. Bioessays. 1994. PMID: 7513153 Review. - Experimental and clinical studies on Rifacinna--the new effective antituberculous drug (review).
Velichka D, Ivana A, Haruaki T, Katsumasa S, Venkata R, Nadadhur G, Donna D, Todor K, Arvind D, Yurii F, Ljudmila Y, Toumanov A, Zvetana Z, Chiaki S. Velichka D, et al. Recent Pat Antiinfect Drug Discov. 2010 Jan;5(1):76-90. doi: 10.2174/157489110790112572. Recent Pat Antiinfect Drug Discov. 2010. PMID: 19929844 Review.
Cited by
- Inactivation of rifampin by Nocardia brasiliensis.
Yazawa K, Mikami Y, Maeda A, Akao M, Morisaki N, Iwasaki S. Yazawa K, et al. Antimicrob Agents Chemother. 1993 Jun;37(6):1313-7. doi: 10.1128/AAC.37.6.1313. Antimicrob Agents Chemother. 1993. PMID: 8328779 Free PMC article. - Ribosylation by mycobacterial strains as a new mechanism of rifampin inactivation.
Dabbs ER, Yazawa K, Mikami Y, Miyaji M, Morisaki N, Iwasaki S, Furihata K. Dabbs ER, et al. Antimicrob Agents Chemother. 1995 Apr;39(4):1007-9. doi: 10.1128/AAC.39.4.1007. Antimicrob Agents Chemother. 1995. PMID: 7785970 Free PMC article. - In vivo activities of newer rifamycin analogs against Mycobacterium avium infection.
Klemens SP, Cynamon MH. Klemens SP, et al. Antimicrob Agents Chemother. 1991 Oct;35(10):2026-30. doi: 10.1128/AAC.35.10.2026. Antimicrob Agents Chemother. 1991. PMID: 1662021 Free PMC article. - Antibiotics: Precious Goods in Changing Times.
Sass P. Sass P. Methods Mol Biol. 2023;2601:3-26. doi: 10.1007/978-1-0716-2855-3_1. Methods Mol Biol. 2023. PMID: 36445576 - Bacterial challenges and evolving antibacterial drug strategy.
Watt B, Collee JG. Watt B, et al. Postgrad Med J. 1992 Jan;68(795):6-21. doi: 10.1136/pgmj.68.795.6. Postgrad Med J. 1992. PMID: 1561196 Free PMC article. Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources